Clinical Trial Update: Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer [Phase 3]

View source ↗

Summary

The Phase 3 trial of fosbretabulin or placebo in combination with carboplatin/paclitaxel for anaplastic thyroid cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Fosbretabulin (fosbretabulin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Mateon Therapeutics | Conditions: Anaplastic Thyroid Cancer | Phase 3 | Status: WITHDRAWN